Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × lazertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1 Expanded_access 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Non-Small Cell Lung Cancer Metastatic 1 Metastatic Non-small Cell Lung Cancers 1 Lung Neoplasms 1 Lazertinib 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1

Interventions

Carboplatin 271 Cisplatin 203 Radiotherapy 171 Paclitaxel 161 Pemetrexed 152 Docetaxel 142 Gemcitabine 131 pembrolizumab 117 Erlotinib Hydrochloride 90 Etoposide 82 Magnetic Resonance Spectroscopy 80 Bevacizumab 70 Specimen Handling 62 Radiosurgery 62 Nivolumab 60 durvalumab 58 Vinorelbine 48 osimertinib 44 Gefitinib 40 Drug Therapy 39 Topotecan 35 Irinotecan 35 atezolizumab 34 Cyclophosphamide 34 Radiation 32 Biopsy 32 Standard of Care 31 Cetuximab 29 Blood Specimen Collection 26 Immunoglobulin G 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Samsung Medical Center

Phase 2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡